Related Experiment Video

Updated: Jan 23, 2026

Generation of a Novel Dendritic-cell Vaccine Using Melanoma and Squamous Cancer Stem Cells
12:43

Generation of a Novel Dendritic-cell Vaccine Using Melanoma and Squamous Cancer Stem Cells

Published on: January 6, 2014

12.2K

When Cancer Vaccines Go Viral

David Repáraz1,2, Diana Llopiz1,2, Pablo Sarobe3,2

  • 1Centro de Investigación Médica Aplicada (CIMA), Universidad de Navarra, Pamplona, Spain.

Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|June 23, 2019
PubMed

Insights

The BN-CV301 vaccine, using a viral prime/boost method, activates immune responses to benefit cancer patients. This platform can be adapted for various antigens to enhance tumor immunity in combination therapies.

Area of Science:

  • Oncology
  • Immunology
  • Vaccinology

Background:

  • Effective cancer vaccines depend on potent immunogens.
  • The BN-CV301 vaccine utilizes a heterologous viral prime/boost strategy.
  • This approach aims to enhance anti-tumor immune responses.

Purpose of the Study:

  • To evaluate the clinical benefit of the BN-CV301 vaccine in cancer patients.
  • To assess the capacity of the viral platform to activate immune responses.
  • To explore the potential of this platform for combinatorial cancer immunotherapy strategies.

Main Methods:

  • Heterologous viral prime/boost immunization with the BN-CV301 vaccine.
  • Assessment of immune response activation.
  • Evaluation of clinical benefit in cancer patients.

Main Results:

  • The BN-CV301 vaccine promoted the activation of immune responses.
  • This immune activation translated into clinical benefit for cancer patients.
  • The viral platform demonstrated adaptability for harboring different antigens.

Conclusions:

  • Heterologous viral prime/boost immunization with BN-CV301 is a viable strategy for inducing anti-tumor responses.
  • The BN-CV301 vaccine platform offers potential for combinatorial approaches in cancer treatment.
  • Further development of this platform may enhance tumor immunity and patient outcomes.

More Related Videos

Expression and Purification of Virus-like Particles for Vaccination06:17

Expression and Purification of Virus-like Particles for Vaccination

Published on: June 2, 2016

22.7K
Intralymphatic Immunotherapy and Vaccination in Mice07:33

Intralymphatic Immunotherapy and Vaccination in Mice

Published on: February 2, 2014

24.0K

Related Concept Videos

Cancer Vaccines01:30

Cancer Vaccines

Cancer treatment vaccines are a rapidly evolving field that offers a promising approach to immunotherapy. Unlike traditional vaccines that prevent diseases, cancer treatment vaccines are designed to treat existing cancers by stimulating the immune system to recognize and attack cancer cells.
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...
985
Vaccinations01:51

Vaccinations

Overview
51.3K
Viral Recombination00:57

Viral Recombination

Cells are sometimes infected by more than one virus at once. When two viruses disassemble to expose their genomes for replication in the same cell, similar regions of their genomes can pair together and exchange sequences in a process called recombination. Alternatively, viruses with segmented genomes can swap segments in a process called reassortment.
25.0K
Viral Structure00:56

Viral Structure

Viruses are extraordinarily diverse in shape and size, but they all have several structural features in common. All viruses have a core that contains a DNA- or RNA-based genome. The core is surrounded by a protective coat of proteins called the capsid. The capsid is composed of subunits called capsomeres. The capsid and genome-containing core are together known as the nucleocapsid.
74.1K
Viral Mutations00:36

Viral Mutations

A mutation is a change in the sequence of bases of DNA or RNA in a genome. Some mutations occur during replication of the genome due to errors made by the polymerase enzymes that replicate DNA or RNA. Unlike DNA polymerase, RNA polymerase is prone to errors because it is not capable of “proofreading” its work. Viruses with RNA-based genomes, like HIV, therefore accrue mutations faster than viruses with DNA-based genomes. Because mutation and recombination provide the raw material...
39.8K
Size and Structure of Viral Genomes01:26

Size and Structure of Viral Genomes

Viral genomes exhibit remarkable diversity in size, structure, and composition, influencing their replication strategies and interactions with host cells. These genomes consist of either DNA or RNA and may be linear or circular. Additionally, they can be single-stranded or double-stranded, with each configuration affecting how the virus propagates within a host. RNA viruses, for instance, generally have smaller genomes than DNA viruses, a factor that contributes to their high mutation rates and...
739